<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025346</url>
  </required_header>
  <id_info>
    <org_study_id>OM/190402/CAPSIMAX</org_study_id>
    <nct_id>NCT04025346</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy of Capsimax on Metabolic Rate</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Efficacy of Capsimax on Metabolic Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Capsimax™ is a proprietary Capsicum Extract that employs Beadlet Technology. In the previous
      study it has been used to investigate its effect in reducing body fat/weight and increase
      metabolic rate. In this study, Capsimax™ will be used to assess effect on Resting Energy
      Expenditure (REE) using Indirect Calorimetry.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Anticipated">January 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double blind, randomized, placebo controlled</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Investigational Product on Resting Energy Expenditure</measure>
    <time_frame>From baseline to 4 hours.</time_frame>
    <description>Assessed by Indirect Calorimetry</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Metabolism</condition>
  <arm_group>
    <arm_group_label>Capsimax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Capsimax</intervention_name>
    <description>1 capsule to be taken before breakfast.</description>
    <arm_group_label>Capsimax</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Micro Crystalline Cellulose</intervention_name>
    <description>1 capsule to be taken before breakfast.</description>
    <arm_group_label>Capsimax</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, adult, male/female participants with age ≥ 18 ≤ 55 years.

          -  A Body Mass Index (BMI) between 18.5 to 29.9 kg/m2.

          -  Fasting blood sugar ≤ 100 mg/dl

          -  Hemoglobin: Males ≥ 11 g/dl and Females ≥ 10 g/dl

          -  BP &lt; 140/90 mmHg

        Exclusion Criteria:

          -  Post-menopausal females

          -  History of hypo/ hyperthyroidism.

          -  History of significant neurological or psychiatric condition such as seizures,
             depression, or insomnia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vedic Lifesciences Pvt. Ltd.</name>
      <address>
        <city>Thāne</city>
        <state>Maharashtra</state>
        <zip>400602</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

